8-K: Quantum-Si Initiates $75 Million At-the-Market Offering with Canaccord Genuity, Terminates Prior Agreement with Evercore

Quantum-Si has entered into an agreement with Canaccord Genuity to sell up to $75 million of its Class A common stock through an at-the-market offering, while simultaneously terminating a similar agreement with Evercore.

Summary

• Quantum-Si Incorporated has established an at-the-market (ATM) offering program to sell up to $75 million of its Class A common stock through Canaccord Genuity LLC.
• The company will pay Canaccord a commission of up to 3.0% of the gross sales price per share sold.
• Quantum-Si has the option to suspend or terminate the sales agreement at any time.
• Concurrently, Quantum-Si terminated its previous ATM offering agreement with Evercore Group L.L.C., under which no shares were sold.
• The offering is being made under an existing shelf registration statement that became effective on August 22, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is taking steps to secure funding, which is positive, but the potential dilution of shares is a concern.

Positives

• The new ATM offering provides Quantum-Si with a flexible way to raise capital.
• The company has the ability to control the timing and amount of shares sold.
• The termination of the previous agreement with Evercore simplifies the company's capital raising strategy.

Negatives

• The company will incur commissions of up to 3.0% on the gross sales price of shares sold.
• The at-the-market offering could potentially dilute existing shareholders.
• There is no guarantee that the company will be able to sell all $75 million of shares.

Risks

• The company's stock price could be negatively impacted by the at-the-market offering.
• The company may not be able to sell all of the shares at the desired price.
• The company's financial performance could be affected by the costs associated with the offering.

Future Outlook

The company may sell shares from time to time through the at-the-market offering program, but has no obligation to sell any specific amount and may suspend or terminate the agreement at any time.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, providing flexibility and control over the timing and amount of shares sold. This move allows Quantum-Si to access capital markets efficiently.

Comparison to Industry Standards

• Many biotech and life sciences companies use at-the-market offerings to raise capital, especially when they are in the development or early commercialization stages.
• The commission rate of up to 3.0% is within the typical range for at-the-market offerings.
• Comparable companies that have used ATM offerings include companies such as Pacific Biosciences, Twist Bioscience, and 10x Genomics.
• These companies often use ATM offerings to fund ongoing research and development, commercialization efforts, and general corporate purposes.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations.
• The company's financial stability may improve with the additional funding.

Next Steps

• Quantum-Si will sell shares through Canaccord Genuity as needed.
• The company will monitor market conditions and its capital needs.
• The company will file required reports with the SEC and Nasdaq.

Key Dates

Keywords

at-the-market offering, equity distribution agreement, common stock, capital raise, Canaccord Genuity, Quantum-Si, sales agent, shelf registration, stock offering